ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT

IND APPLICATION FOR JSKN021 WAS OFFICIALLY ACCEPTED BY THE CDE

This announcement is made by Alphamab Oncology (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders (the "**Shareholders**") and potential investors of the Group about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that the Investigational New Drug (the "**IND**") application for JSKN021, an independently developed dual payload bispecific antibody-drug conjugate ("**ADC(s)**") targeting epidermal growth factor receptor ("**EGFR**")/human epidermal growth factor receptor 3 ("**HER3**"), has been officially accepted by the Center for Drug Evaluation (the "**CDE**") of the National Medical Products Administration of China (國家藥品監督管理局) (the "**NMPA**").

The Company plans to initiate a phase I clinical study of JSKN021 for the treatment of advanced malignant solid tumors, aiming to evaluate its safety, tolerability, pharmacokinetics and antitumor activity in such patient population and to determine the maximum tolerated dose and/or recommended Phase II dose.

According to preclinical data presented at the 2025 annual meeting of American Association for Cancer Research, JSKN021 inhibited the growth of cancer cells with either HER3 or EGFR or both expressions. Furthermore, JSKN021 showed stronger tumor inhibition efficacy than mono payload ADCs in multiple CDX models. For further details, please refer to the Company's announcement dated April 30, 2025.

ABOUT JSKN021

JSKN021 is a first-in-class dual payload bispecific ADC consisting of an EGFR/HER3 bispecific antibody conjugated with novel topoisomerase I inhibitor ("**T01**") and Monomethyl auristatin E ("**MMAE**"). Engineered with finely tuned binding avidity in both arms to address tumor heterogeneity while minimizing on-target, off-tumor toxicity, JSKN021 was designed for enhanced stability and improved homogeneity. It combines T01 (drug-to-antibody ratio ("**DAR**") 4) and MMAE (DAR 2) payloads to overcome non-response and resistance observed with single-payload treatment strategies.

ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in the PRC with a fully integrated proprietary technology platform in ADCs, bispecific antibodies and multi-functional protein engineering. The Company's highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology, including, among others, one product approved for marketing by the NMPA and multiple products in phase III or pivotal clinical trial stages. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop and/or ultimately market JSKN021 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, March 13, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.